Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Lorundrostat demonstrated strong efficacy and safety in the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. These ...

Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.

Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water. Normally ...

The aldosterone-renin ratio (ARR) has gained popularity as a screening test for primary hyperaldosteronism, a probably underdiagnosed cause of hypertension. However, studies have yielded varying ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

K yushu University researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas (APAs)-adrenal gland tumors that drive high blood pressure. Using cutting-edge ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.